TMCnet News

InVivo Therapeutics Announces Key Opinion Leader Event and Company Update with Robert Langer, Sc.D., and Nicholas Theodore, M.D.
[December 01, 2015]

InVivo Therapeutics Announces Key Opinion Leader Event and Company Update with Robert Langer, Sc.D., and Nicholas Theodore, M.D.


InVivo Therapeutics Holdings Corp. (NVIV) today announced the company will host a Key Opinion Leader (KOL) Event and Company Update in New York on Thursday, December 3 from 5-7PM ET.

The meeting will feature presentations by two renowned key opinion leaders: Bob Langer, Sc.D., the David H. Koch Institute Professor at Massachusetts Institute of Technology and co-founder of InVivo; and Nick Theodore, M.D., Chief of Spinal Surgery at the Barrow Neurosurgical Institute and the neurosurgeon who performed the first Neuro-Spinal Scaffold™ implantation. Dr. Langer will discuss his contributions to the development of the field of biomaterials and InVivo's product candidates that evolved from work performed in his laboratory. Dr. Theodore will present current state-of-the-art surgical treatment of spinal cord injury patients and a case study of the first patient in InVivo's ongoing Neuro-Spinal Scaffold study. In addition, Mark Perrin, Chief Executive Officer and Chairman of InVivo, and members of InVivo's executive management team will provide several important company updates.

"We are very pleased to be joined by such accomplished and well-respected thought leaders for our first company-hosted analyst and investor presentation. Dr. Langer and Dr. Theodore will share their unique perspectives on their respective fields and InVivo's pioneering work," Perrin said. "The company has made tremendous progress over the last year, and we are pleased to be able to have the opportunity to share these significant accomplishments."



The event will be broadly accessible via a live webcast through http://lifesci.rampard.com/20151203 that will begin at 5:15PM ET on the day of the event. A replay of the webcast will be available soon after the event's conclusion at the same URL.

In-person attendance is by invitation only with RSVP required.


About the Neuro-Spinal Scaffold™

Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple (News - Alert) Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company's investigational Neuro-Spinal Scaffold received the 2015 Becker's Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.


[ Back To TMCnet.com's Homepage ]